Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients.
fingolimod
modified Rio score (MRS)
natalizumab
no evidence of disease activity (NEDA)
relapsing-remitting type of multiple sclerosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
22 Apr 2021
22 Apr 2021
Historique:
received:
03
03
2021
revised:
12
04
2021
accepted:
20
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal responders to treatment. The aim of our study was to identify factors that would predict poor response to treatment with natalizumab and fingolimod. In the multicenter prospective trial, 336 subjects were enrolled, initiating therapy with natalizumab ( NEDA-3 after the first year of therapy was 73.9% for natalizumab and 54.8% for fingolimod ( We conclude that switching to the second-line therapy should occur earlier to enable better results for patients treated with natalizumab or fingolimod. The outcome on both drugs is better with better neurological conditions and lower MRS of the patient on the platform therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal responders to treatment. The aim of our study was to identify factors that would predict poor response to treatment with natalizumab and fingolimod.
METHODS
METHODS
In the multicenter prospective trial, 336 subjects were enrolled, initiating therapy with natalizumab (
RESULTS
RESULTS
NEDA-3 after the first year of therapy was 73.9% for natalizumab and 54.8% for fingolimod (
CONCLUSION
CONCLUSIONS
We conclude that switching to the second-line therapy should occur earlier to enable better results for patients treated with natalizumab or fingolimod. The outcome on both drugs is better with better neurological conditions and lower MRS of the patient on the platform therapy.
Identifiants
pubmed: 33922368
pii: jcm10091830
doi: 10.3390/jcm10091830
pmc: PMC8122749
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2017 Jan 12;12(1):e0169546
pubmed: 28081190
Mult Scler. 2016 Sep;22(10):1315-26
pubmed: 27230789
J Neurol. 2017 Dec;264(12):2351-2374
pubmed: 28879412
Lancet Neurol. 2009 Mar;8(3):254-60
pubmed: 19201654
Ther Adv Neurol Disord. 2018 Oct 25;11:1756286418805713
pubmed: 30386435
Neurotherapeutics. 2020 Jan;17(1):208-217
pubmed: 31452082
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Mult Scler Relat Disord. 2019 Aug;33:146-152
pubmed: 31200271
Lancet Neurol. 2014 Jun;13(6):545-56
pubmed: 24685276
Neurology. 2011 Apr 5;76(14):1200-1
pubmed: 21346219
Mult Scler. 2019 Jul;25(8):1141-1149
pubmed: 29985084
Ther Adv Neurol Disord. 2019 Jan 25;12:1756286418823462
pubmed: 30719080
PLoS One. 2019 Oct 24;14(10):e0223863
pubmed: 31647829
J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):271-277
pubmed: 31974130
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
Eur Neurol. 2020;83(1):25-33
pubmed: 32187609
Mult Scler. 2014 Oct;20(12):1602-8
pubmed: 24622350
Mult Scler. 2013 Apr;19(5):605-12
pubmed: 23012253